Targets › IFNAR2
7 programs from 7 companies in 25 trials: 13 Phase 2, 6 Phase 3, 4 Phase 1, 2 Phase 4; Oncology, Infectious disease, Neurology; next expected readout Mar 2027.
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. (UniProt, P48551)
Open in Phaseline: the race on IFNAR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PharmaEssentia | Ropeginterferon Alfa-2B (P1101) Interferon alpha/beta receptor positive modulator | IFNAR1, IFNAR2 | Phase 3 | Polycythemia Vera; Primary Myelofibrosis; Essential Thrombocythemia; Primary Myelofibrosis (PMF) … | Mar 2027 |
| Biogen | Peginterferon Beta-1A (BIIB017) Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | May 2027 |
| BriaCell Therapeutics | Interferon Alfa-2B Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 3 | Breast Cancer; Colorectal Neuroendocrine Tumor G1; Prostate Adenocarcinoma; Polycythemia Vera | Dec 2027 |
| Xiamen Amoytop Biotech | Peginterferon Alfa-2B Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | Essential Thrombocythemia; Hepatitis B, Chronic; Malignant Melanoma | Sep 2027 |
| Brii Biosciences | Peginterferon Alfa-2A Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection; Chronic Hepatitis b; Chronic Hepatitis B | Sep 2028 |
| Diakonos Oncology | Peginterferon Alfa-2A Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | Glioblastoma (GBM) | Mar 2030 |
| M.D. Anderson Cancer Center | Recombinant Interferon Alpha 2b-like Protein Type I interferon receptor agonist | IFNAR1, IFNAR2 | Phase 1 | Stage III Hepatocellular Carcinoma AJCC v8 | Feb 2028 |
Polycythemia Vera (3) Essential Thrombocythemia (3) Chronic Hepatitis b (2) Glioblastoma (GBM) (1) Primary Myelofibrosis (1) Primary Myelofibrosis (PMF) (1) Chronic Myeloid Leukemia (1) Cutaneous T Cell Lymphoma (1) Ropeginterferon (1) Myelofibrosis (1) Breast Cancer (1) Colorectal Neuroendocrine Tumor G1 (1)
mixed (4), protein or peptide (3)
Diakonos Oncology (1) PharmaEssentia (1) BriaCell Therapeutics (1) Brii Biosciences (1) Xiamen Amoytop Biotech (1) Biogen (1) M.D. Anderson Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.